Magnolia Medical Technologies

Magnolia Medical Technologies is a privately held company based in Seattle, Washington. With 110 employees, they have generated $20.8 million in revenue. Founded with a mission to eliminate errors in in-vitro diagnostic testing, Magnolia Medical Technologies develops and markets innovative solutions for healthcare institutions. Their flagship product, Steripath, is a technology platform designed to address the critical issue of contamination, which can lead to misdiagnoses of bloodstream infections, including sepsis. By providing accurate and rapid test results, Steripath aims to prevent unnecessary and prolonged antibiotic therapy and reduce the incidence of false-positive CLABSIs. Magnolia Medical Technologies differentiates itself through its evidence-based technology platform, Steripath, and its commitment to providing unparalleled support to clients. Their extensive intellectual property portfolio, consisting of over 100 issued patents and 70+ pending applications, underscores their dedication to innovation and addressing the root causes of diagnostic errors. To learn more about Magnolia Medical Technologies and their solutions, visit their website at magnolia-medical.com.